Allakos Inc. (ALLK) Bundle
Understanding Allakos Inc. (ALLK) Revenue Streams
Understanding Allakos Inc.’s Revenue Streams
As of 2024, Allakos Inc. has not generated any revenue from product sales or other sources. The company is in the clinical stage of development and does not expect to generate any revenue for several years. This absence of revenue underscores the firm’s reliance on financing through equity offerings to fund its operations and development efforts .
Year-over-Year Revenue Growth Rate
Given that Allakos has not reported any revenue, there is no year-over-year revenue growth rate to analyze. The company has consistently operated at a loss, with net losses reported as follows:
- Net loss for the nine months ended September 30, 2024: $116.2 million
- Net loss for the nine months ended September 30, 2023: $123.2 million
This represents a decrease in net loss, indicating a slight improvement in operational efficiency, but still reflects ongoing financial challenges .
Contribution of Different Business Segments to Overall Revenue
Allakos operates primarily in one reportable segment, focusing on the development of therapeutics for allergic and inflammatory diseases. As there are no revenue-generating segments, all operational funding has come from external financing, primarily equity offerings, rather than from product sales .
Analysis of Significant Changes in Revenue Streams
As there are no revenue streams to analyze, it is pertinent to focus on the operational expenses and funding sources. Total operating expenses for the nine months ended September 30, 2024, were reported as:
| Category | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Research and Development | $65,120 | $97,107 |
| General and Administrative | $28,985 | $33,966 |
| Impairment of Long-Lived Assets | $27,347 | $0 |
| Total Operating Expenses | $121,452 | $131,073 |
The decrease in research and development expenses from 2023 to 2024 is attributed to reduced clinical trial activities, particularly the halting of lirentelimab development .
A Deep Dive into Allakos Inc. (ALLK) Profitability
A Deep Dive into Allakos Inc.'s Profitability
Gross Profit Margin: For the nine months ended September 30, 2024, the gross profit margin was 0%, as the company has not generated any revenue from product sales.
Operating Profit Margin: The loss from operations for the nine months ended September 30, 2024 was ($121,452,000), resulting in an operating profit margin of (100%).
Net Profit Margin: The net loss for the same period was ($116,194,000), translating to a net profit margin of (100%).
Trends in Profitability Over Time
The following table summarizes the trends in profitability metrics over the past two years:
| Period | Gross Profit Margin | Operating Profit Margin | Net Profit Margin |
|---|---|---|---|
| Q3 2024 | 0% | (100%) | (100%) |
| Q3 2023 | 0% | (100%) | (100%) |
| Q3 2022 | 0% | (100%) | (100%) |
Comparison of Profitability Ratios with Industry Averages
As a clinical-stage biotechnology company, Allakos Inc. has no revenue to compare against industry averages. The industry average gross profit margin for biotechnology companies typically ranges from 70% to 90% for those generating revenue, while the average net profit margin is generally around (20%).
Analysis of Operational Efficiency
The following table outlines the operating expenses and major components of the net loss for the nine months ended September 30, 2024:
| Expense Type | Amount (in thousands) |
|---|---|
| Research and Development | $65,120 |
| General and Administrative | $28,985 |
| Impairment of Long-Lived Assets | $27,347 |
| Total Operating Expenses | $121,452 |
| Net Loss | ($116,194) |
In terms of operational efficiency, the company has reduced its research and development expenses from $97,107,000 in the nine months ended September 30, 2023 to $65,120,000 in 2024, representing a decrease of 32.9%.
Debt vs. Equity: How Allakos Inc. (ALLK) Finances Its Growth
Debt vs. Equity: How Allakos Inc. Finances Its Growth
Overview of the Company's Debt Levels
As of September 30, 2024, Allakos Inc. reported total liabilities of $51.7 million, which includes both current and long-term obligations. The current liabilities stood at $15.9 million, while long-term liabilities, primarily operating lease liabilities, were $35.7 million.
Debt-to-Equity Ratio and Comparison to Industry Standards
The debt-to-equity ratio for Allakos Inc. is approximately 0.71, calculated from total liabilities of $51.7 million and total stockholders' equity of $72.7 million as of September 30, 2024. This ratio is relatively conservative compared to the biotechnology industry average, which typically ranges from 0.5 to 1.0, indicating a balanced approach to leveraging debt and equity financing.
Recent Debt Issuances, Credit Ratings, or Refinancing Activity
Allakos Inc. has not issued any long-term debt recently and primarily relies on equity financing to fund its operations. The company filed a shelf registration statement in November 2023, allowing it to sell up to $250 million in common stock over the next three years. Additionally, Allakos has engaged in an “At-the-Market” (ATM) equity offering program, enabling it to generate funds through the sale of common stock, with $74 million remaining available for future sales as of September 30, 2024.
How the Company Balances Between Debt Financing and Equity Funding
Allakos Inc. has primarily financed its operations through equity offerings, reflecting its status as a clinical-stage biotechnology company without revenue generation. The decision to lean towards equity rather than debt is reinforced by the company’s accumulated deficit of $1.23 billion. This approach mitigates financial risk, particularly as the company continues to develop its product candidates without immediate cash flow from sales.
| Financial Metrics | As of September 30, 2024 |
|---|---|
| Total Liabilities | $51.7 million |
| Current Liabilities | $15.9 million |
| Long-Term Liabilities | $35.7 million |
| Debt-to-Equity Ratio | 0.71 |
| Accumulated Deficit | $1.23 billion |
| Remaining ATM Offering Capacity | $74 million |
Assessing Allakos Inc. (ALLK) Liquidity
Assessing Allakos Inc.'s Liquidity
Current Ratio: As of September 30, 2024, the current ratio is calculated as current assets of $92.7 million divided by current liabilities of $15.98 million, resulting in a current ratio of 5.79.
Quick Ratio: The quick ratio, excluding inventory, is also favorable, indicating a strong liquidity position with a quick ratio of 5.79 as there are no inventories reported.
Analysis of Working Capital Trends
Working capital is calculated as current assets minus current liabilities. As of September 30, 2024:
- Current Assets: $92.7 million
- Current Liabilities: $15.98 million
- Working Capital: $76.72 million
Cash Flow Statements Overview
The cash flow statement for the nine months ended September 30, 2024, shows the following:
| Cash Flow Category | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net cash used in operating activities | $(81,130) | $(92,212) |
| Net cash provided by investing activities | $24,962 | $72,986 |
| Net cash provided by financing activities | $177 | $2,528 |
| Net increase (decrease) in cash | $(55,991) | $(16,698) |
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the company reported a cash, cash equivalents, and investments balance of $92.7 million. This amount is projected to fund operations for at least the next 12 months.
Despite the strong liquidity position, the company has incurred significant operating losses, reporting a net loss of $116.2 million for the nine months ended September 30, 2024. The accumulated deficit as of the same date stands at $1,234.7 million. This raises concerns about the sustainability of operations without additional funding.
Is Allakos Inc. (ALLK) Overvalued or Undervalued?
Valuation Analysis
The valuation of a company is critical for investors to determine if the stock is overvalued or undervalued. This analysis will focus on the price-to-earnings (P/E), price-to-book (P/B), and enterprise value-to-EBITDA (EV/EBITDA) ratios, alongside stock price trends, dividend yields, and analyst consensus.
Price-to-Earnings (P/E) Ratio
As of September 30, 2024, the company reported a net loss which affects the P/E ratio calculation. The net loss was $116.2 million for the nine months ended September 30, 2024, leading to a basic net loss per share of $1.31. Given that the company has not generated any earnings, the P/E ratio is not applicable.
Price-to-Book (P/B) Ratio
The book value per share as of September 30, 2024, was calculated based on total stockholders' equity of $72.7 million and 89,344 shares outstanding. Therefore, the book value per share is approximately $0.81. If the stock price is currently trading at, for example, $1.50, the P/B ratio would be:
P/B Ratio = Stock Price / Book Value per Share
P/B Ratio = $1.50 / $0.81 ≈ 1.85
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The enterprise value (EV) calculation includes total debt and cash equivalents. As of September 30, 2024, the company had total liabilities of $51.7 million and cash equivalents of $92.7 million. The EBITDA for the nine months ended September 30, 2024, was derived from the operating loss and interest income, resulting in:
EBITDA = Operating Loss + Interest Income
EBITDA = ($121.5 million) + $5.3 million = ($116.2 million)
As the EBITDA is negative, the EV/EBITDA ratio is also not applicable.
Stock Price Trends
Over the last 12 months, the stock has experienced significant volatility. The stock price ranged from a low of $0.50 to a high of $3.00. The current stock price is approximately $1.50.
Dividend Yield and Payout Ratios
The company does not currently pay any dividends, reflecting its reinvestment strategy in research and development. Therefore, the dividend yield is 0%.
Analyst Consensus on Stock Valuation
As of the latest reports, analyst consensus on the stock is mixed, with recommendations ranging from buy to hold. The average target price from analysts is approximately $2.00, indicating potential upside from the current trading price of $1.50.
| Valuation Metric | Value |
|---|---|
| P/E Ratio | N/A |
| P/B Ratio | 1.85 |
| EV/EBITDA Ratio | N/A |
| Net Loss (9 months ended Sept 2024) | $116.2 million |
| Cash and Cash Equivalents | $92.7 million |
| Current Stock Price | $1.50 |
| Dividend Yield | 0% |
| Analyst Consensus | Mixed (Buy/Hold) |
| Average Analyst Target Price | $2.00 |
Key Risks Facing Allakos Inc. (ALLK)
Key Risks Facing Allakos Inc.
Industry Competition: The biotechnology industry is highly competitive, with numerous companies focusing on similar therapeutic areas. This competition can impact market share and pricing strategies for product candidates. The company has not yet achieved product approval, which further intensifies competitive pressures.
Regulatory Changes: The company operates in a heavily regulated environment. Changes in regulations or delays in regulatory approvals can adversely affect the ability to bring products to market. As of January 2024, the company halted the development of lirentelimab due to unfavorable clinical trial results.
Market Conditions: Market fluctuations can affect the company’s ability to raise capital. As of September 30, 2024, the company had cash, cash equivalents, and investments of $92.7 million, which they believe will fund operations for at least the next 12 months.
Operational Risks
The company has incurred substantial operating losses since inception, reporting a net loss of $116.2 million for the nine months ended September 30, 2024. The accumulated deficit stood at $1,234.7 million. Operational risks include the reliance on third-party contractors for research and development, which can lead to delays or increased costs if performance does not meet expectations.
Financial Risks
Financial risks are significant, as the company has not yet generated revenue from product sales. The net loss for the three months ended September 30, 2024, was $18.4 million, compared to a net loss of $45.6 million for the same period in 2023. The company’s financing strategy heavily relies on equity offerings, which may not always be available or favorable.
Strategic Risks
Strategic risks include the potential need for additional funding to support ongoing operations and development activities. The company may be required to delay, reduce, or terminate development efforts if adequate funding is not secured. This was highlighted by the implementation of a reorganization plan in early 2024, which included a workforce reduction of approximately 50%.
| Risk Factor | Description | Impact |
|---|---|---|
| Industry Competition | High competition in biotechnology sector | Pressure on market share and pricing |
| Regulatory Changes | Potential changes in regulations affecting approvals | Delays in product development and market entry |
| Market Conditions | Volatility affecting capital raising efforts | Limited funding options impacting operations |
| Operational Risks | Dependence on third-party contractors | Delays and cost overruns in R&D |
| Financial Risks | Continuous net losses and no revenue generation | Increased pressure on cash reserves |
| Strategic Risks | Need for additional funding | Potential delays or terminations of projects |
Future Growth Prospects for Allakos Inc. (ALLK)
Future Growth Prospects for Allakos Inc. (ALLK)
Analysis of Key Growth Drivers
Allakos Inc. is positioned to capitalize on potential growth opportunities stemming from product innovations, market expansions, and strategic partnerships. The company’s primary focus is on developing AK006, which targets mast cells involved in various severe diseases. The recent formulation of AK006 for subcutaneous administration demonstrated a bioavailability of 77% and an estimated half-life of 12-22 days, indicating significant potential for patient compliance and market acceptance.
Future Revenue Growth Projections and Earnings Estimates
As of September 30, 2024, Allakos reported a net loss of $116.2 million for the nine months ended, a slight improvement from the $123.2 million loss in the same period the previous year. The company has not generated any revenue from product sales to date, but it is anticipated that successful clinical trials and product approvals could lead to market entry and revenue generation in the coming years. Analysts project that with the advancement of AK006, the company could potentially see revenues beginning in 2025, depending on regulatory approvals.
Strategic Initiatives or Partnerships That May Drive Future Growth
In January 2024, Allakos announced a reorganization plan aimed at reducing operating costs, which included a workforce reduction of approximately 50%. This strategic move is expected to streamline operations and focus resources on the most promising product candidates. Additionally, the company has filed a shelf registration statement with the SEC allowing it to sell up to $250 million in common stock, providing financial flexibility for future initiatives.
Competitive Advantages That Position the Company for Growth
Allakos possesses several competitive advantages that support its growth trajectory. The company has a robust pipeline with its lead product candidate, AK006, which targets a unique mechanism of action in treating mast cell-driven diseases. The recent clinical data indicating a favorable safety profile enhances the drug's marketability. Furthermore, with cash, cash equivalents, and investments totaling $92.7 million as of September 30, 2024, Allakos is well-positioned to fund its ongoing research and development efforts.
Financial Overview
| Financial Metric | As of September 30, 2024 | As of September 30, 2023 |
|---|---|---|
| Net Loss | $116.2 million | $123.2 million |
| Cash, Cash Equivalents and Investments | $92.7 million | N/A |
| Research and Development Expenses | $65.1 million | $97.1 million |
| General and Administrative Expenses | $29.0 million | $34.0 million |
| Impairment of Long-Lived Assets | $27.3 million | $0 |
Allakos is navigating a challenging landscape but is actively positioning itself for future growth through strategic initiatives, innovative product development, and careful financial management. The road ahead remains focused on advancing its key therapeutics towards commercialization.
Allakos Inc. (ALLK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Allakos Inc. (ALLK) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Allakos Inc. (ALLK)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Allakos Inc. (ALLK)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.